» Articles » PMID: 35033061

Relationship Between Gut Microbiota and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: a 1-year Follow-up Study

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2022 Jan 16
PMID 35033061
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by a persistent limitation in airflow. Gut microbiota is closely correlated with lung inflammation. However, gut microbiota has not been studied in patients with declining lung function, due to chronic lung disease progression.

Subjects And Methods: Stool samples were obtained from 55 patients with COPD that were in stable condition at enrolment (stage 1) and at a 1-year follow-up (stage 2). After extracting stool DNA, we performed next generation sequencing to analyse the distribution of gut microbiota.

Results: Patients were divided to control and declining lung function groups, based on whether the rate of forced expiratory volume in 1 s (FEV) had declined over time. An alpha diversity analysis of initial and follow-up stool samples showed a significant difference in the community richness of microbiota in the declining function group, but not in the control group. At the phylum level, Bacteroidetes was more abundant in the control group and Firmicutes was more abundant in the declining function group. The Alloprevotella genus was more abundant in the control group than in the declining function group. At 1-year follow-up, the mean proportions of Acinetobacter and Stenotrophomonas significantly increased in the control and declining function groups, respectively.

Conclusion: Some community shifts in gut microbiota were associated with lung function decline in COPD patients under regular treatment. Future studies should investigate the mechanism underlying alterations in lung function, due to changes in gut bacterial communities, in COPD.

Citing Articles

Gut microbiota in chronic obstructive pulmonary disease varies by CT-verified emphysema status.

Rotevatn A, Eagan T, Tangedal S, Husebo G, Ostridge K, Nielsen R Eur Clin Respir J. 2025; 12(1):2470499.

PMID: 40017817 PMC: 11866649. DOI: 10.1080/20018525.2025.2470499.


Metabolic pathways from the gut metatranscriptome are associated with COPD and respiratory function in lung cancer patients.

Dora D, Revisnyei P, Mihucz A, Kiraly P, Szklenarik G, Dulka E Front Cell Infect Microbiol. 2024; 14:1381170.

PMID: 39635041 PMC: 11616033. DOI: 10.3389/fcimb.2024.1381170.


Air pollution, dysbiosis and diseases: pneumonia, asthma, COPD, lung cancer and irritable bowel syndrome.

Agarwal S, Tomar N, Makwana M, Patra S, Chopade B, Gupta V Future Microbiol. 2024; 19(17):1497-1513.

PMID: 39345043 PMC: 11492635. DOI: 10.1080/17460913.2024.2401263.


Double-side role of short chain fatty acids on host health via the gut-organ axes.

Gao Y, Yao Q, Meng L, Wang J, Zheng N Anim Nutr. 2024; 18:322-339.

PMID: 39290857 PMC: 11406094. DOI: 10.1016/j.aninu.2024.05.001.


Beneficial Bacteria in the Gut Microbiota May Lead to Improved Metabolic and Immunological Status in Chronic Obstructive Pulmonary Disease.

Passos F, de Oliveira L, Jesus F, Zanette D, Neto O, Neves M Med Sci (Basel). 2024; 12(3).

PMID: 39189204 PMC: 11348168. DOI: 10.3390/medsci12030041.


References
1.
Berg K, Wright J . The Pathology of Chronic Obstructive Pulmonary Disease: Progress in the 20th and 21st Centuries. Arch Pathol Lab Med. 2016; 140(12):1423-1428. DOI: 10.5858/arpa.2015-0455-RS. View

2.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

3.
Pauwels R, Rabe K . Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004; 364(9434):613-20. DOI: 10.1016/S0140-6736(04)16855-4. View

4.
Barnes P . Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014; 35(1):71-86. DOI: 10.1016/j.ccm.2013.10.004. View

5.
Barnes P . Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138(1):16-27. DOI: 10.1016/j.jaci.2016.05.011. View